Results of Intravitreal Anti‑Vascular Endothelial Growth Factor Therapy in Inflammatory Choroidal Neovascularization

To report the visual outcomes of intravitreal (IVT) anti‑vascular endothelial growth factor (anti‑VEGF) in inflammatory choroidal neovascularization (iCNV).

A retrospective study of 43 eyes of 38 patients with active choroidal neovascularization (CNV) related to ocular inflammatory disease, treated with IVT injections of anti‑VEGF (bevacizumab, ranibizumab, or aflibercept), with or without associated systemic anti‑inflammatory therapy, at Fattouma Bourguiba University Hospital, Monastir, Tunisia (24 eyes of 23 patients) and at Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy (19 eyes of 15 patients) from January 1, 2013, to December 31, 2018.

The mean age was 35.5 ± 16.4 years. The sex ratio male:female was 0.27. Seventeen eyes (39.5%) of 17 patients (44.7%) had only anti‑VEGF injections, and 26 eyes (60.5%) of 21 patients (45.3%) had anti‑VEGF injections and associated systemic anti‑inflammatory therapy. Bevacizumab was injected in 36 eyes (83.7%), ranibizumab in six eyes (14%), and aflibercept in one eye (2.3%). Mean follow‑up was 20.3 ± 19.2 months(range, 6–106 months). Mean visual acuity improved from 0.8 ± 0.37 logMAR (approximate Snellen equivalent 20/125) to 0.51 ± 0.42 logMAR (approximate Snellen equivalent 20/63) (P < 0.001). Mean central macular thickness on optical coherence tomography decreased from 403.7 ± 121.9 to 293.7 ± 82.8 µm (P < 0.001). Mean gain of vision was 2.9 ± 3.1 lines. The mean number of injections was 2.5. Twenty eyes (46.5%) received a single injection. There were no side effects related to the IVT injections of anti‑VEGF.

CNV is a sight‑threatening complication of uveitis. IVT anti‑VEGF seems to be an effective and safe treatment for iCNV when inflammation is controlled.